Rein Therapeutics Begins Enrolling Patients In Phase 2 RENEW Trial

Benzinga Newsdesk www.benzinga.com Positive 83.9%

Neg 0% Neu 0% Pos 83.9%

Global Expansion Complete as Germany Joins Ongoing Study of Inhaled LTI-03 in Idiopathic Pulmonary Fibrosis
- Company on track to report initial topline data in 2H 2026

Comments

No comments yet. Be the first!